Navigation Links
ViroPharma to Present at Two June Healthcare Conferences
Date:6/2/2009

EXTON, Pa., June 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Colin Broom, MD, vice president and chief scientific officer of ViroPharma, will present at the 30th Annual Goldman Sachs Global Healthcare Conference at 3:45 P.M. ET on Tuesday, June 9, 2009. The conference is being held at the Grand Hyatt in New York City.

ViroPharma also announced that William Roberts, vice president, corporate communications will present at the Jefferies & Company 3rd Annual Healthcare Conference at 10:15 A.M. ET on Thursday, June 18, 2009. The conference is being held at the Mandarin Oriental in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
2. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
3. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
4. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
6. ViroPharma to Present at Three November Healthcare Conferences
7. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
8. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
9. ViroPharma to Present at Three October Healthcare Conferences
10. ViroPharma to Present at Three September Healthcare Conferences
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017   Valentin A. Pavlov, PhD ... , president and CEO of The Feinstein Institute ... analysis of how the nervous system regulates the immune ... bioelectronic medicine devices to treat disease and ... Neuroscience . The paper examines various studies ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/14/2017)... 13, 2017  The Alliance for Safe Biologic Medicines ... FDA final guidance on biologic naming: ... in emphasizing the importance of distinct naming for all ... the benefits biosimilars will bring to patients, including new ... the portion of the Guidance dealing with suffix design ...
(Date:1/13/2017)... and Markets has announced the addition of the "Global Biopolymers Market ... ... 16.83% during the period 2017-2021. The report covers the ... 2017-2021. To calculate the market size, the report considers the revenue generated ... a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
Breaking Biology News(10 mins):